NP
ATOS icon

NorthRock Partners’s Atossa Therapeutics ATOS Stock Holding History

NorthRock Partners’s Portfolio ATOS Stock Details ATOS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-1,117
Closed -$14.5K – 644
2025
Q3 		$14.5K Hold
1,117
– – ﹤0.01% 868
2025
Q2 		$13.9K Hold
1,117
– – ﹤0.01% 681
2025
Q1 		$11.3K Hold
1,117
– – ﹤0.01% 774
2024
Q4 		$15.8K Hold
1,117
– – ﹤0.01% 712
2024
Q3 		$25.5K Hold
1,117
– – ﹤0.01% 728
2024
Q2 		$19.9K Buy
+1,117
New +$24.7K ﹤0.01% 719

Other funds holding ATOS

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

NorthRock Partners's ATOS Position: Q4 2025 in Review

NorthRock Partners sold out of Atossa Therapeutics (ATOS) in Q4 2025, closing a stake of 1,117 shares — an estimated $14.5K sold.

NorthRock Partners first reported a position in ATOS in Q2 2024 and held it in 6 quarters. The position peaked at $25.5K in Q3 2024. 67 funds tracked by Wall St. Rank hold ATOS as of Q4 2025.

  • NorthRock Partners reported no remaining Atossa Therapeutics position as of Q4 2025 after selling out during the quarter.
  • NorthRock Partners sold 1,117 Atossa Therapeutics shares in Q4 2025, an estimated $14.5K.
  • NorthRock Partners first reported a position in Atossa Therapeutics in Q2 2024 and held it in 6 quarters.
  • NorthRock Partners's Atossa Therapeutics position peaked at $25.5K in Q3 2024.
  • 67 funds tracked by Wall St. Rank held Atossa Therapeutics as of Q4 2025.

Based on NorthRock Partners's 13F filing for Q4 2025, filed 17 Feb 2026.